How We Rate Peptides: What “Best” Means

On this page

“Best” is easy to claim and hard to define. This page explains what it means here, how we order peptides for a goal, what our labels mean, and what a ranking does not tell you.

What does “best” mean here?

Best means the strongest published evidence that a peptide helps with a goal. It doesn’t mean safe, and it doesn’t mean right for you. We rank by the type of evidence first, then its quality and its result. A rank isn’t a recommendation. If no peptide has good evidence for a goal, we say so.

Any commercial relationship is disclosed next to the content it touches. See our editorial policy for the full rules.

How do we order peptides for a goal?

Each guide’s ranking table carries this note: ordered by the strength of the evidence that it helps with this goal: the type of study first, then its quality and its result. A rank isn’t a recommendation.

In practice we work through three questions, in this order.

What type of study is it? A controlled trial in people counts for more than an uncontrolled human study, which counts for more than an animal study, which counts for more than a lab study. The four types are below.
How good is it? We look at whether it had a comparison group, how many people it enrolled, how long it ran, whether it measured something that matters to a person (illness, function, survival) or only a lab marker, whether it was published in a journal or only announced by a company, and who paid for it.
What did it find? A well-run trial that finds no benefit does not rank above a well-run trial that does. Result matters because “best” means the strongest evidence that it helps.

We do not order by popularity, search volume or how often a peptide is mentioned online.

What happens when a company’s number differs from the journal’s?

Sometimes the same trial is reported in two ways: a company’s announcement and the journal article can use different statistical analyses. Terms like “efficacy estimand” and “treatment-regimen estimand” describe those choices. Lilly’s release on a retatrutide trial defines its “efficacy estimand” as the effect had all randomized participants remained on treatment, and reports the treatment-regimen figure, which the journal uses, separately. In our guides we use the journal’s main analysis as the primary number, explain the other one if we mention it, and do not compare a company’s figure with journal figures for other treatments.

What are the four types of evidence?

These are the same definitions used on every guide and on our editorial policy.

Human trials: controlled trials in people, published in a journal, that tested a clinical outcome and showed a benefit. The strongest kind of evidence we report.
Limited human data: small, short or inconclusive human studies, including observational studies, uncontrolled trials and controlled trials that did not show a clinical benefit.
Animal studies: results in animals often don’t carry over to people.
Lab studies: cells or tissue in a dish. An early signal, not an answer.

A few consequences of these rules:

A trial that was small, measured only a lab marker, failed, or was reported only in a conference abstract goes in Limited human data, even though it was controlled. An imaging result can count when it is the basis of an FDA-approved use, and we say so next to it.
The evidence bars show the type of evidence. They are not a score for how good a peptide is.
If a peptide’s best evidence is a hormone level or another marker, we say so next to it.
Many of our study summaries rely on the published abstract, not the full paper. Where we rely only on a company’s description of a study, we say so.

What do our status labels mean?

FDA-approved: the FDA approved a specific product for the uses on its label. That doesn’t extend to compounded versions or other uses.
Compounded versions: not FDA-approved. Generally made by a pharmacist or physician for an individual patient. Compounded drugs are not FDA-approved, which means the FDA doesn’t review their safety, effectiveness or quality before they’re marketed.
Investigational: being studied in people, and not FDA-approved for that use.
Animal studies only: we found no published human studies as of the date we checked.
Not FDA-approved: no FDA approval, and none of the other labels applies.

Why do goal guides say “FDA-approved for…”?

Because an approved drug is approved for specific uses. Before FDA approves a drug, a company must show it is safe and effective for its intended uses. So next to a goal, we write “FDA-approved for” followed by the use on the label, or “FDA-approved for other uses” when the goal isn’t on the label. Approval for one use does not mean approval for another.

Is “not FDA-approved” always the same thing?

No, and we explain the difference where it matters. FDA does not have authority to approve dietary supplements before they are sold, and cosmetics are not required to have FDA approval before sale. So for a supplement or a cosmetic, “not FDA-approved” describes how the whole category works. For a compounded or investigational peptide, it means the product has not been through FDA’s approval process.

How do we check regulatory status?

We check the U.S. regulatory status of each peptide on the day we publish, and we show that date on the page. Status can change after that date. Where something is changing, such as a pending decision or an interim policy, we say that it is and we describe what it is and is not. We write “enforcement discretion” or “has said it does not intend to take enforcement action,” never “legal now,” “cleared” or “approved,” unless FDA approval is the fact.

Where do our claims come from?

Every factual claim links to its source. We prioritize FDA, PubMed, ClinicalTrials.gov, peer-reviewed journals and primary press releases. When we rely on a secondary source, we link to it. Each guide is checked against its cited sources before it’s published. We do not use trial registrations that we cannot confirm are real studies.

What do we not publish?

We don’t publish doses, cycles or mixing instructions for unapproved peptides. For approved medicines, we point to the FDA label and a clinician. We don’t promise cures or results, and we don’t publish before-and-after claims. We don’t link to or recommend “research use only” or gray-market sellers for human use.

Who writes this, and who checks it?

Guides carry the byline of the Best Peptides For Editorial Team. We use AI tools to help research, write and check our pages. A “Reviewed by” line appears only when a named person actually reviewed the page, with the date. When we find an error, we correct the guide in place, update its date and list it on our corrections page.

Frequently asked questions

Does “best” mean safe?

No. Best means the strongest published evidence that a peptide helps with a goal. A peptide can have strong evidence of benefit and still carry serious warnings.

Does a higher rank mean I should use it?

No. A rank isn’t a recommendation. Whether a treatment is right for you depends on your health, your other medicines and your clinician’s judgment.

What if no peptide has good evidence for a goal?

We say so. In several of our guides, we found no peptide with good human evidence for the goal.

Why do you rank approved drugs above unapproved peptides?

We don’t rank by approval status. We rank by the type and strength of the evidence. Approved drugs often rank higher because they have controlled trials, but an approved drug can rank lower if its evidence for a particular goal is weaker, and we show approval separately.

Are your pages medical advice?

No. They are educational. See our medical disclaimer.

Sources we checked

FDA: compounding laws and policies (compounded drugs are not FDA-approved)FDA. Accessed October 31, 2026.
FDA: understanding unapproved use of approved drugs ("off label")FDA. Accessed October 31, 2026.
FDA: step 3, clinical research (phases of clinical trials)FDA. Accessed October 31, 2026.
FDA: questions and answers on dietary supplementsFDA. Accessed October 31, 2026.
FDA authority over cosmetics: how cosmetics are not FDA-approved, but are FDA-regulatedFDA. Accessed October 31, 2026.

Written and maintained by the Best Peptides For Editorial Team. How we rate evidence.